Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The Molecular Basis of Ovarian Cancer Grading

EF 2011-12

Résumé
Ovarian cancer affects 1 in 70 women in Canada, many of whom fail to notice its presence until the cancer has metastasized. Survival can be greatly increased by early detection, particularly because treatment decisions are primarily based on information about tumour size, spread and appearance. Tumour size and spread are called "stage", while tumour appearance under a microscope is called "grade". Stage and grade are intended to provide information about patient outcome and survival. The importance of stage is uncontroversial, but recent studies have indicated that grade has little value in making treatment decisions. In this study, I propose that grade II and III tumours are actually the same entity, and could be treated as a single group. To test this hypothesis, I will comprehensively survey the serous ovarian cancer transcriptome and contrast genes associated with well-, moderately-, and poorly-differentiated tumours. I will assess the association of these genes with patient survival, and consider their function in the cell. This study will integrate new genomic data with traditional clinical data to facilitate treatment planning.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
255013
Name
Yao Qianli
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The Molecular Basis of Ovarian Cancer Grading
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biological Pathway; Gene Expression; Hierchical Clustering; Kaplan-Meier Estimator; Microarray; Ovarian Cancer; Prognostic Marker; Survival Analysis; Univariate Linear Model; Unsupervised Machine Learning
Abstract
Ovarian cancer affects 1 in 70 women in Canada, many of whom fail to notice its presence until the cancer has metastasized. Survival can be greatly increased by early detection, particularly because treatment decisions are primarily based on information about tumour size, spread and appearance. Tumour size and spread are called "stage", while tumour appearance under a microscope is called "grade". Stage and grade are intended to provide information about patient outcome and survival. The importance of stage is uncontroversial, but recent studies have indicated that grade has little value in making treatment decisions. In this study, I propose that grade II and III tumours are actually the same entity, and could be treated as a single group. To test this hypothesis, I will comprehensively survey the serous ovarian cancer transcriptome and contrast genes associated with well-, moderately-, and poorly-differentiated tumours. I will assess the association of these genes with patient survival, and consider their function in the cell. This study will integrate new genomic data with traditional clinical data to facilitate treatment planning.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yao, Qianli
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~